The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 80.00
Bid: 78.50
Ask: 81.50
Change: 0.00 (0.00%)
Spread: 3.00 (3.822%)
Open: 80.00
High: 80.00
Low: 80.00
Prev. Close: 80.00
BSV Live PriceLast checked at -
British Smaller Companies VCT is an Investment Trust

To maximise Total Return and provide investors with an attractive long-term tax-free dividend yield while maintaining the Company's status as a venture capital trust.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3rd Quarter Results

21 Mar 2022 13:15

RNS Number : 4701F
British Smaller Companies VCT PLC
21 March 2022
 

British Smaller Companies VCT plc

Interim Management Statement

For the quarter ended 31 December 2021

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 31 December 2021. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

The Company's Total Return at 31 December 2021 was 251.9 pence per ordinary share, representing an increase of 1.6 pence per ordinary share over the Total Return of 250.3 pence per ordinary share as at 30 September 2021. The increase is 1.8 per cent of the opening net asset value at the beginning of the quarter of 90.9 pence per share.

The Company completed the realisation of 15 per cent of its investment in Matillion as part of its Series E funding round during the quarter. The proceeds from this partial exit were £5.0 million which, together with previous proceeds received of £2.1 million, represents a total return to date of 2.7x the total cost of the Company's investment. The value of the Company's residual investment in Matillion at 31 December 2021 is £29.7 million. This is an outstanding outcome to date, in a company which is experiencing continued fast growth.

Total proceeds from all full and partial realisations in the quarter were £6.4 million, a gain of £3.5 million over cost. £0.2 million was invested in the quarter.

Following its previously announced offer for subscription (alongside British Smaller Companies VCT2 plc, together "the Offers"), on 7 January 2022 the Company made the first and final issue of ordinary shares pursuant to the Offers by allotting 39,514,174 ordinary shares of 10 pence each, raising gross proceeds of £34.6 million (£33.2 million net).

Performance

The movement in Total Return in pence per ordinary share is set out in the table below:

 

30 September 2021

Increase in Value

Dividends paid/shares issued

Buyback of shares

Movement

In Period

31 December 2021

Net Assets (£m)

131.7

2.5

(5.4)

(0.4)

(3.3)

128.4

NAV per share (PPS)

90.9

1.6

(5.0)

-

(3.4)

87.5

Cumulative dividends paid (PPS)

159.4

-

5.0

-

5.0

164.4

Total Return (PPS)

250.3

1.6

-

-

1.6

251.9

Shares in issue

144,873,228

-

2,306,826

(526,365)

1,780,461

146,653,689

The unaudited NAV increased in value by 1.6 pence; after payment of 5.0 pence of dividends, the unaudited NAV per ordinary share stood at 87.5 pence per share at the period end. Cumulative dividends paid at 31 December 2021 were 164.4 pence per ordinary share (30 September 2021: 159.4 pence per ordinary share).

 

The movements in NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 30 September 2021

131.7

90.9

Increase in portfolio value

3.0

2.0

Net operating costs

(0.5)

(0.4)

2.5

1.6

Issue/buy-back of shares

1.4

-

Total Return in the period

3.9

1.6

NAV before the payment of dividends

135.6

92.5

Dividends paid

(7.2)

(5.0)

NAV at 31 December 2021

128.4

87.5

 

Following payment of the third interim dividend of 2.0 pence per ordinary share for the year ending 31 March 2022 on 5 January 2022 the unaudited net asset value is 85.5 pence per ordinary share.

Dividends and shares in issue

On 16 November 2021, the Company issued 2,306,826 shares under the DRIS, following the payment of the second interim dividend.

 

Under its standing buyback authority, on 15 December 2021 the Company purchased 526,365 shares at 80.21 pence at a cost of £0.42 million. These shares are held in treasury.

 

Subsequent to the quarter end, on 5 January 2022 the Company issued 940,963 shares under the DRIS following the payment of the third interim dividend, and on 7 January 2022 the Company issued 39,514,174 shares arising from the Offers, taking the number of shares in issue to 187,108,826 at that date, with a further 17,986,301 shares held in treasury.

Net assets

Net assets at 31 December 2021 comprised the following:

£000

% of net assets

Unquoted investments at fair value

95,297

74.2

Listed investment funds

5,146

4.0

Cash and cash equivalents

27,056

21.1

Other net current assets

873

0.7

Net assets

128,372

100.0

 

Investments

The investment portfolio at 31 December 2021 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion Limited

29,655

23.1%

Springboard Research Holdings Limited

5,938

27.7%

Intelligent Office UK

4,744

31.4%

Wooshii Limited

4,743

35.1%

Unbiased EC1 Limited

4,624

38.7%

Elucidat Ltd

4,397

42.1%

SharpCloud Software Limited

4,392

45.6%

Force24 Ltd

4,160

48.8%

ACC Aviation Group Limited

3,661

51.7%

Displayplan Holdings Limited

3,512

54.4%

69,826

54.4%

Other investments

25,471

19.8%

Total investments

95,297

74.2%

Investments made since November 2015 represented 77 per cent of the value of the unquoted portfolio at 31 December 2021.

Portfolio performance

Over the quarter to 31 December 2021, the aggregate portfolio valuation has increased by £3.0 million.

Ukraine

During the build up to and subsequent to the recent invasion of Ukraine by Russia, we have been closely monitoring the impact of the war on our portfolio. There is minimal direct impact, which has principally been where two portfolio companies have had a small section of their software development teams based in Ukraine. From a business perspective, continuity of supply and service has been secured, although we are aware of a small number of developers who we believe are directly caught in the conflict and our thoughts are with them and all those suffering the humanitarian impact of the war.

Outlook

The current environment is clearly a demanding one for many companies, dealing with supply chain inflation, a competitive hiring environment and wider political challenges. But as the pandemic has shown, the key to a company's success is having a strong management team, ready access to capital and remaining agile. We are confident that the Company's portfolio is well placed to navigate these challenges. We also continue to see a number of promising investment opportunities and look forward to updating you on progress with deploying the Company's newly raised funds over the coming quarters.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

21 March 2022

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Alex Collins Panmure Gordon (UK) Limited Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTEAADFASKAEFA
Date   Source Headline
3rd Apr 20247:58 amRNSIssue of Equity and Close of Offers
26th Mar 202411:11 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
20th Mar 202412:00 pmRNSPublication of Supplementary Prospectus
15th Mar 202412:15 pmRNS3rd Quarter Results
16th Feb 20243:52 pmRNSClose of Offers to New Applications
16th Feb 20243:51 pmRNSClose of Offers to New Applications
30th Jan 20249:23 amRNSIssue of Equity
18th Dec 20234:02 pmRNSTransaction in Own Shares
13th Dec 20234:00 pmRNSOffer Update
13th Dec 20234:00 pmRNSStrategy/Company/Ops Update
8th Dec 20239:47 amRNSPayment of Dividend and Issue of Equity
24th Nov 20237:00 amRNSHalf-year Report
26th Oct 20231:34 pmRNSDividend Declaration
24th Oct 20231:20 pmRNSOffer Update
24th Oct 20231:19 pmRNSOffer Update
6th Oct 202310:19 amRNSOffer Update
6th Oct 202310:17 amRNSOffer Update
27th Sep 20238:21 amRNSOffer Update
26th Sep 20238:20 amRNSTransaction in Own Shares and PDMR
20th Sep 202312:30 pmRNSPublication of a Prospectus
20th Sep 202312:30 pmRNSPublication of a Prospectus
14th Sep 202310:28 amRNSResult of AGM
14th Sep 202310:28 amRNSResult of General Meeting
13th Sep 20237:00 amRNS1st Quarter Results
2nd Aug 202310:25 amRNSNew combined offer for subscription
2nd Aug 202310:25 amRNSNew combined offer for subscription
28th Jul 202310:00 amRNSDirector/PDMR Shareholding
28th Jul 202310:00 amRNSPayment of Dividend and Issue of Equity
27th Jun 20237:45 amRNSTransaction in Own Shares
21st Jun 20231:00 pmRNSPublication of Circular
16th Jun 202312:00 pmRNSAnnual Financial Report
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:23 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:42 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNS3rd Quarter Results
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSDirector/PDMR Shareholding
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:48 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.